2022 Ljubljana, Slovenia

II-18 Yin Edwards
Exposure-safety analysis of Tovorafenib (DAY101), an investigational oral pan-RAF kinase inhibitor, in oncology patients with solid tumors
Wednesday 15:10-16:40